Published by Josh White on 31st August 2023
(Sharecast News) - Biopharmaceutical developer Ovoca Bio's shares were plummeting on Thursday, after it released a summary of the top-line results from its phase two dose-ranging study evaluating Orenetide.
URL: http://www.digitallook.com/dl/news/story/33739201/...